BELITE BIO INC - AMER

Belite Bio Announces PMDA Submission of Tinlarebant for Stargardt Disease Clinical Trial in Japan

22 Mar 2024 07:00:00 By Nasdaq GlobeNewswire

Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website

11 Mar 2024 21:28:39 By Nasdaq GlobeNewswire

Belite Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

11 Mar 2024 20:27:47 By Nasdaq GlobeNewswire

Belite Bio to Host Webcast on March 12, 2024, to Discuss Fourth Quarter and Full Year 2024 Financial Results

06 Mar 2024 07:00:01 By Nasdaq GlobeNewswire

Belite Bio to Participate in the Leerink Partners Global Biopharma Conference

04 Mar 2024 07:00:00 By Nasdaq GlobeNewswire

Belite Bio to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

07 Feb 2024 07:00:00 By Nasdaq GlobeNewswire

Belite Bio to Participate in the Benchmark Company’s Upcoming Discovery One-on-One Investor Conference

30 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

Belite Bio to Participate in the BTIG Ophthalmology Day

20 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

Belite Bio Reports Third Quarter 2023 Operational Highlights and Financial Results

13 Nov 2023 19:15:47 By Nasdaq GlobeNewswire

Belite Bio to Host Webcast on November 14, 2023, to Discuss Third Quarter 2023 Financial Results

07 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

Belite Bio Presents Results from a 24-month, Phase 2 Study of Tinlarebant in Childhood-onset Stargardt Disease at the AAO Annual Meeting

06 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

Belite Bio Announces Presentation at the American Academy of Ophthalmology 2023 Annual Meeting

27 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

Belite Bio Reports Second Quarter 2023 Operational Highlights and Financial Results

08 Aug 2023 21:17:28 By Nasdaq GlobeNewswire

Belite Bio to Host Webcast on August 9, 2023 to Discuss Second Quarter 2023 Financial Results

04 Aug 2023 07:00:00 By Nasdaq GlobeNewswire

Belite Bio Doses First Subject in Pivotal Phase 3 PHOENIX Trial Evaluating Oral Tinlarebant for GA

27 Jul 2023 16:00:00 By Nasdaq GlobeNewswire

Belite Bio Announces Pricing of $30 Million Underwritten Public Offering of American Depositary Shares and Warrants

30 May 2023 19:49:26 By Nasdaq GlobeNewswire

Belite Bio Announces Proposed Underwritten Public Offering of American Depositary Shares and Warrants

30 May 2023 15:01:00 By Nasdaq GlobeNewswire

Belite Bio Reports First-Quarter 2023 Operational Highlights and Financial Results

10 May 2023 18:58:59 By Nasdaq GlobeNewswire

Belite Bio to Host Webcast on May 11, 2023 to Discuss First Quarter 2023 Financial Results

10 May 2023 14:33:22 By Nasdaq GlobeNewswire

Belite Bio to Host Key Opinion Leader Webinar Discussing Progression of Childhood-onset STGD1 and Relevance of the Tinlarebant 18-month Phase 2 Data

04 May 2023 10:09:06 By Nasdaq GlobeNewswire